

Composition of the Board of Directors of sanofi-aventis

Paris, France – December 15, 2010 – At its meeting held on December 15, 2010, the Board of Directors co-opted a new independent Director, Carole Piwnica.

This co-optation will be submitted to the ratification of the General Meeting of Shareholders that will take place on May 6, 2011. As a result of this co-optation, the new Board of Directors is composed of 14 members of whom half are independent Directors.

The new Board of Directors would consist of the following members: Serge Weinberg (Chairman) Christopher A. Viehbacher (Chief Executive Officer), Uwe Bicker, Carole Piwnica, Robert Castaigne, Thierry Desmarest, Lord Douro, Jean-René Fourtou, Claudie Haigneré, Igor Landau, Christian Mulliez, Lindsay Owen-Jones, Klaus Pohle, Gérard Van Kemmel.

Biography of Carole Piwnica

Carole Piwnica is a lawyer and member of the bar of New York and Paris. She started her career in 1985 at *Proskauer Rose*, New York, before joining the merger & acquisitions department of *Shearman & Sterling*, Paris, in 1987. She was General Counsel at *Gardini et Associés* from 1991 to 1994 when she joined *Amylum Group* where she was appointed Chairman in 1996. That same year, she was appointed Vice-president and Board Member of *Tate & Lyle Plc*, a world leader in sugar derivatives. Since 2006, Carole Piwnica has been Chief Executive Officer of *Naxos UK Ltd*, a company specialized in private equity consulting.

She is a Board Member of *Eutelsat*, a French satellite provider, *Louis Delhaize*, a Belgian distribution company, and *Aviva*, a UK-based insurance company. Carole Piwnica is a Belgian citizen.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more information, please visit www.sanofi-aventis.com.